{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:28:12Z","timestamp":1777930092104,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T00:00:00Z","timestamp":1240790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Onkologie"],"abstract":"<jats:p>Die Kombination von Doxorubicin und Cisplatin wurde in einer Phase-II-Studie bei Patienten mit fortgeschrittenen malignen Pleuramesotheliomen untersucht. 19 Patienten erhielten intraven\u00f6s Cisplatin 60 mg\/m2\/Tag, Tag 1 und 2, und Doxorubicin 40 mg\/m2 am Tag 3, alle 4 Wochen. Bei 8\/19 Patienten (46%) wurde ein Ansprechen auf die Behandlung gesehen: 2 Patienten erreichten eine komplette Remission (CR) und 6 eine partielle Remission (PR). Die mediane Remissionsdauer betrug 222 Tage, die mediane \u00dcberlebenszeit aller Patienten war 370 Tage, verglichen mit einer medianen \u00dcberlebenszeit von 273 Tagen in einer historischen Kontrollgruppe von 30 Patienten, die nur operiert wurden. Insbesondere die gastrointestinale Toxizit\u00e4t war betr\u00e4chtlich. Nach unserer Erfahrung ist die Behandlung wirksam bei Patienten mit malignen Pleuramesotheliomen, die Nebenwirkungen begrenzen allerdings die m\u00f6gliche Behandlungsdauer.<\/jats:p>","DOI":"10.1159\/000216501","type":"journal-article","created":{"date-parts":[[2009,4,27]],"date-time":"2009-04-27T08:49:09Z","timestamp":1240822149000},"page":"118-120","source":"Crossref","is-referenced-by-count":10,"title":["Phase-II Study with the Combination of Cisplatin and Doxorubicin in Advanced Malignant Mesothelioma of the Pleura"],"prefix":"10.1159","author":[{"given":"H.","family":"Hen\u00df","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.H.","family":"Fiebig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Schildge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,4,27]]},"container-title":["Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/216501","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000216501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:03:32Z","timestamp":1777680212000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000216501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,27]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000216501","archive":["Portico"],"relation":{},"ISSN":["0378-584X","1423-0240"],"issn-type":[{"value":"0378-584X","type":"print"},{"value":"1423-0240","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,27]]}}}